All issues
Volume 28 (1975)
- Issue 6 Pages 727-
- Issue 5 Pages 655-
- Issue 4 Pages 415-
- Issue 3 Pages 283-
- Issue 2 Pages 125-
- Issue 1 Pages 1-
Predecessor
Volume 28, Issue 2
Displaying 1-16 of 16 articles from this issue
- |<
- <
- 1
- >
- >|
-
RYOCHI FUJII, HAJIME YOSHIOKA, TAKASHI NAKAMURA, SUSUMU NAKAZAWA, MAKO ...1975 Volume 28 Issue 2 Pages 125-131
Published: April 25, 1975
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS -
HARUYUKI OTA, YOSHIRO OGUCHI, HIROMASA SAKAGUCHI, AKIYOSHI SHU, MASAZU ...1975 Volume 28 Issue 2 Pages 132-136
Published: April 25, 1975
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS -
TOYOKO OGURI, MITSUHARU MURASE, NOZOMU KOSAKAI1975 Volume 28 Issue 2 Pages 137-142
Published: April 25, 1975
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESSWe determined the drug susceptibility of Serratia-Enterobacter group isolated from clinical materials between October 1973 and May 1974 by disk method and agar plate dilution method, and compared the drug susceptibility and multiple resistance among pigment-producing Serratia, pigment non-producing Serratia and Enterobacter. We used following drugs for susceptibility tests; ampicillin, carbenicillin, sulbenicillin, cephaloridine, streptomycin, kanamycin, dibekacin, gentamicin, chloramphenicol, tetracycline, colistin, nalidixic acid, nitrofrantoin and erythromycin.
Above one half of strains of Serratia and Enterobacter was isolated from sputa and pharyngeal swabs.
Almost all strains of Serratia and Enterobacter were resistant to ampicillin, cephaloridine and erythromycin, but sensitive to gentamicin and dibekacin. Resistant strains were more found in Serratia than in Enterobacter. Pigment non-producing strains of Serratia were more sesistant to chemotherapeutics than pigment producing strains. There were many multiple resistant strains in Serratia and Enterobacter, especially in pigment non-producing strains of Serratia, and the strains isolated from urine were resistant to more drugs compared with the strains from other materials.View full abstractDownload PDF (926K) -
MICHIO TSUKAMURA1975 Volume 28 Issue 2 Pages 143-148
Published: April 25, 1975
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESSTherapeutic effect of lividomycin was observed in patients with infections of the respiratory tract (infections in association with bronchiectasis, mixed infections of cavities after negative conversion of tubercle bacilli, pneumonia, and so forth). Significant improvement of clinical symptoms was observed in 15 cases and no improvement in 4 cases.
Lividomycin was administered at a dose of 1 g/day for 3-15 days. Staphylococcus aureus (9 cases), Klebsiella pneumoniae (1 case), α-hemolytic Streptococcus (3 cases), Aerococcus (4 cases) and Pseudomonas aeruginosa (1 case) were suggested to be causative organisms in the above-mentioned patients.(In one case, however, causative organism was not determined.) Lividomycin seemed to be effective in cases of infections with Staphylococcus aureus, α-hemolytic Streptococcus and Klebsiella pneumoniae, whereas not effective in a case of infection with Pseudomonas aeruginosa.
In order to differentiate causative organisms from the organisms constantly existing on the upper respiratory tract, alkali treatment was employed as an aid for the determination of the causative organisms. However, further studies are desirable for the evaluation of this procedure.View full abstractDownload PDF (900K) -
HIROTUNE KONDO, TARO MIWA, SUHACHIRO YOKOUCHI, YOSHITERU ANDO1975 Volume 28 Issue 2 Pages 149-154
Published: April 25, 1975
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESSClinical effects of a newly developed aminoglycoside antibiotic lividomycin, were investigated in 13 patients suffering from respiratory infections.
1. A total of 13 patients with the following infectious diseases was treated with 1 g/day of lividomycin for 3-11 days (average 6.7 days): Acute pneumonia 3 cases, bronchiectasis 3 cases, acute bronchitis 5 cases, suppurative diseases of the lung 1 case, and pyothorax 1 case.
As the results, the antibiotic was effective in 5 patients, moderately effective in 4 patients and ineffective in 4 patients, and thus the global effective rate was 62.9% (9/13).
2. As in the case of kanamycin, lividomycin indicated fairly good sensitivity against a total of 17 strains comprising Staphylococcus aureus (7 strains), α-Streptococcus (2 strains), β-Streptococcus (3 strains), γ-Streptococcus (1 strain), Neisseria (2 strains) and Haemophilus (2 strains) which were isolated from sputum.
3. No side effects attributable to lividomycin were observed.View full abstractDownload PDF (805K) -
TAKESHI MASHIMA, GENICHIRO TERADA1975 Volume 28 Issue 2 Pages 155-165
Published: April 25, 1975
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESSPatients with various respiratory infections, primarily wet cases of bronchiectasis, were treated with lividomycin (LVDM) at a dose of 1 g/day for about a week. The results obtained are as follows:
1. Of the 15 patients with refractory bronchiectasis who had previously been treated with various other antibiotics, 11 patients (73.3%) responded to LVDM. Although there was no patient who responded to LVDM excellently, good cures were achieved in 5 patients and fair cures in 6 patients.
2. In bronchiectasis patients having infections in association with pulmonary tuberculosis (mixed infections), LVDM did not show any remarkable effects, excepting that fair cures were achieved in 3 patients.
3. In the 7 patients with acute bronchopneumonia, excellent, good and fair cures were achieved in 1, 5 and 1 patient, respectively. Although LVDM was effective in all of the patients with the said infection, the number of the patients responded excellently was meager and the onset of action seemed to be somewhat slow.
4. In one patient with lobar pneumonia, LVDM was not effective.
5. The MIC values of LVDM for clinically isolated various organisms are summarized below: Pseudomonas aeruginosa 50 mcg/ml, Klebsiella pneumoniae 3.13-6.25 mcg/ml, Haemophilis influenzae 1.56-6.25 mcg/ml, Diplococcus pneumoniae 50 mcg/ml, α-Streptococcus 50-100 mcg/ml, β-Strepto-coccus 100 mcg/ml, and Staphylococcus aureus 1.56 mcg/ml.
6. In spite of the fact that a majority of the patients participated in this study were the aged, LVDM's side effects were limited to an increase of BUN (one patient) and eruption (one patient). Any noticeable changes in hepatic and renal function, hearing acuity, etc. were not observed.
As indicated above, LVDM was effective against respiratory infections as well as infections of the urinary tract on which a considerable number of research has already been reported. Thus, it is considered to be worthwhile to use LVDM for the treatment of respiratory infections.View full abstractDownload PDF (1210K) -
TERUO AOYAGI, TAKESHI KAWAI, YUKIHIRO YAMADA, JIRO GOMI, KOJI OGIWARA, ...1975 Volume 28 Issue 2 Pages 166-174
Published: April 25, 1975
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESSTherapeutic effects of lividomycin (LVDM) were studied in 33 patients with respiratory infections including pneumonia, lung abscess, chronic bronchitis, etc. LVDM was intramuscularly administered at the dose of 1 or 2 g per day for consecutive 4-25 days.
The results obtained are summarized below: 1. At the end of the first week of the treatment, rate of improvement in such parameters as cough, sputum, rales, fever and blood sedimentation rate were 69%, 56.7%, 60%, 79.2% and 70%, respectively. Also, in 16% of the patients, abnormal shadow noted in X-ray film of the chest was disappeared and in 20% of the patients, size of the same was reduced during the first week of the treatment.
2. Therapeutic effects of LVDM were evaluated synthetically and were graded as excellent, good, fair and ineffective. LVDM was effective in about 70% of the patients, that is, excellent results were obtained in 4 patients, good in 12 patients, fair in 6 patients, and in 10 patients this antibiotic was ineffective.
3. In one patient with slight loss of high frequency perception was observed on the audiogram, but no other ototoxic effects such as subjective hearing loss, tinnitus, etc. In addition, no untoward effects on renal and hepatic function were observed.
4. The MIC values of LVDM for clinically isolated 20 strains of Pseudomonas aeruginosa were examined, using kanamycin for comparison. The MIC values of LVDM for many strains were superior to those of kanamycin.
In view of the test results mentioned above, LVDM would appear to be a useful medication for the treatment of some of respiratory infections.View full abstractDownload PDF (4397K) -
SHOICHI INOUE, MASAO SAKAI, MASAO NAKANE, TAKAO KITAMURA, KANEYASU MIY ...1975 Volume 28 Issue 2 Pages 175-178
Published: April 25, 1975
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS -
SEISHI TERAO1975 Volume 28 Issue 2 Pages 179-187
Published: April 25, 1975
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS -
A. Local stimulation test. B. Granulation testYOSHIO HARADA, TOMOYUKI HANABUSA1975 Volume 28 Issue 2 Pages 188-194
Published: April 25, 1975
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS -
II Chronic toxicityMASAAKI KURAMOTO, YASUKO ISHIMURA, JUNKO MORIMOTO, SHIUNG-YI LEE, TSUN ...1975 Volume 28 Issue 2 Pages 195-203
Published: April 25, 1975
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS -
YUZO HAYASHI, MINORU MATSUURA, HIROSHI NARA, KIYOSHI IMAI, AKIHIRO HAR ...1975 Volume 28 Issue 2 Pages 205-230
Published: April 25, 1975
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS -
YUZO HAYASHI, HITOSHI FURUKAWA, YUJI KAWANO, TADASHI YOSHIDA1975 Volume 28 Issue 2 Pages 231-242
Published: April 25, 1975
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS -
HIROSHI TAKEDA, SHOICHI MATSUMURA, MAMORU UNO, MOTOHIKO UEDA1975 Volume 28 Issue 2 Pages 243-248
Published: April 25, 1975
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS -
An analysis in dogsKEN-ICHI YAMAMOTO, SHIZUO UTSUMI, TORU SAWADA, YUKIO NAITO, KOJI YOSHI ...1975 Volume 28 Issue 2 Pages 249-264
Published: April 25, 1975
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS -
1975 Volume 28 Issue 2 Pages e1-
Published: 1975
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS
- |<
- <
- 1
- >
- >|